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ABSTRACT
Objectives: To determine the prevalence of pneumococcal serotypes and antimicrobial susceptibility in 
patients with meningitis, and to evaluate the implications for vaccine coverage. Methods: Pneumococ-
cal strains obtained from normally sterile ﬂ uids from patients admitted with meningitis were isolated 
at the Hospital de Clínicas of the Universidade Federal de Uberlândia, Minas Gerais State, and sent to 
the Instituto Adolfo Lutz, city of São Paulo, São Paulo State, for further identifi cation, serotyping, and 
antimicrobial susceptibility determination. Results: From April 1999 to April 2009, 338 pneumococ-
cal strains were isolated, and 72 obtained from patients with meningitis, were analyzed. Patients’ ages 
varied from one month to 82.2 years (mean of 18.4 ± 22.9 years; median of 5.2 years) and 46 (63.9%) 
patients were male. Strains were isolated from cerebrospinal ﬂ uid [66 occasions (91.7%)] and blood 
[6 occasions (8.3%)]. The most commonly identifi ed serotypes were 14, 19F, 3, 7F, 6A, 6B, 10A, 18C, 
23F, 5, and 34. Of the 20 [27.8%] oxacillin-resistant strains, 17 [23.6%] were resistant to penicillin and 
nine [12.5%] to ceftriaxone, both resistance patterns being more common in children aged two years 
or less and during the 2005-2009 period. Conclusions: Resistance to penicillin and ceftriaxone was de-
tected in 23.6% and 12.5% of the strains, respectively, and predominated in children aged two years or 
less and during the 2005-2009 period. There were 24 different serotypes of pneumococcus and 79.8% 
of the serotypes were represented in the 7-valent conjugated vaccine [PVC7].
Keywords: Streptococcus pneumoniae; meningitis; serotyping; pneumococcal vaccines; drug 
resistance.
[Braz J Infect Dis 2011;15(1):22-27]©Elsevier Editora Ltda.
INTRODUCTION
Streptococcus pneumoniae is one of the most 
common agents of pneumonia, meningitis, 
acute otitis media, and sinusitis in children.1,2 
It accounts for high morbidity and mortal-
ity rates in children under the age of fi ve years 
and adults over the age of 65 years,2 especially 
in developing countries.3 The World Health Or-
ganization estimates that from 800 thousands 
to one million children die every year due to 
invasive pneumococcal disease, and more than 
90% of the deaths occur in developing coun-
tries.4 Meningitis is one of the least common 
manifestations of pneumococcal disease and 
has the highest rates of morbidity (late neuro-
logical sequelae in approximately 40%5 to 58%6) 
and lethality (up to 50%6) in developing coun-
tries. In the USA, prior to the appearance of the 
Haemophilus infl uenzae type B (Hib) conjugate 
vaccine, approximately 95% of the meningitis 
cases in children under the age of two years were 
caused by the bacteria Hib, meningococcus, and 
pneumococcus.7 In Brazil, pneumococcus is the 
second causative agent of bacterial meningitis, 
and in the 2001-2006 period, its mean lethality 
coeffi cient was 30%, much higher than those of 
meningococcus (17.6%) and Hib (19.8%).8
The clinical course of the pneumococcal dis-
ease is inﬂ uenced by several factors, such as treat-
ment adequacy. The treatment for pneumococcal 
infections is based on initial antibiotic therapy, 
which is usually empirical regarding the etiology 
and in vitro susceptibility to antimicrobial agents. 
Based on bacterial isolation in culture and anti-
microbial susceptibility tests, antibiotic therapy 
can be then properly adjusted. Penicillin is the 
drug of choice for many pneumococcal diseases;1 
however, with the increasing report of penicillin-
resistant strains since the 1980s, alternative regi-
mens have been proposed.9,10 
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The prevention of invasive disease is mainly based on ac-
tive immunization.1,2 According to the capsular polysaccharide 
antigen, 91 different serotypes,11,12 contained in 46 pneumo-
coccal serogroups,13 have been described so far. A 7-valent vac-
cine (PCV7. Prevenar®. Pfi zer/Wyeth Pharmaceuticals, Inc.) 
containing the capsular polysaccharide of serotypes 4, 6B, 9V, 
14, 18C, 19F, and 23F, conjugated with a protein carrier, was 
licensed in the USA in 2000.14 The immunogenicity of the poly-
saccharide is widened by the covalent binding with the protein 
molecule, particularly in children under the age of two years, 
and the vaccine protects against nasopharyngeal colonization 
by the serotypes it contains.14 The following two conjugate 
vaccines have been recently licensed in several countries: the 
13-valent (PCV13. Prevenar13® Pfi zer/Wyeth Pharmaceuticals, 
Inc.) produced with the same protein carrier according to the 
same conjugation process, which, compared to PCV7, adds the 
capsular polysaccharide antigen of serotypes 1, 3, 5, 6A, 7F, and 
19A;15 and the 10-valent (PCV10. Synﬂ orix®. GlaxoSmithKline 
Biologics AS), which uses different protein carriers and, as 
compared to PCV7, adds serotypes 1, 5, and 7F.15 
Because the antibiotic resistance pattern and pneumo-
coccal serotype prevalence vary in different populations, 
in different geographical regions and, probably, over time, 
establishing the profi le of the most prevalent serotypes in 
a certain community and knowing the resistance rates are 
important to better assess vaccine coverage and to support 
the choice of initial empiric treatment. 
OBJECTIVES
To document the serotype profi le and susceptibility to anti-
microbial agents of pneumococcal strains obtained from pa-
tients hospitalized with meningitis at the Hospital das Clíni-
cas of the Universidade Federal de Uberlândia (HC-UFU), in 
addition to assessing the implications for the antipneumo-
coccal vaccine coverage rates.
PATIENTS AND METHODS
This is a prospective, case-series, laboratory-surveillance study, 
whose laboratory data of serotyping and in vitro susceptibility 
to antimicrobial agents of invasive pneumococcal strains were 
obtained from patients admitted to the HC-UFU. The index 
case is a pneumococcal strain isolated at the Clinical Analysis 
Laboratory from clinical specimens (blood or cerebrospinal 
ﬂ uid) of a patient hospitalized with meningitis. Aseptically ob-
tained specimens were properly processed and inoculated in 
hemoculture bottles (blood sample) or in chocolate-agar and 
blood-agar plates (other sample types) right after collection 
and immediately after arrival at the laboratory. Only one pneu-
mococcal isolate per patient per hospitalization was considered 
in the study. The pneumococcal strains were isolated and iden-
tifi ed at the HC-UFU according to internationally described 
methods and subsequently sent to the Bacteriology Sector of 
the Instituto Adolfo Lutz (IAL), in the city of São Paulo, for spec-
imen confi rmation, serotyping, and determination of in vitro 
susceptibility to antimicrobial agents.16 Pneumococcal strains 
were lyophilized in 20% skim milk and properly catalogued. 
The following two fi ndings characterized a case of meningitis: 
pneumococcal isolation in the cerebrospinal ﬂ uid; or clinical 
and laboratory fi ndings of meningitis accompanied by the iso-
lation of the agent in blood.
Antimicrobial susceptibility was assessed by using the disk 
diffusion test with oxacillin (1 µg), tetracycline, oﬂ oxacin, chlo-
ramphenicol, erythromycin, sulfamethoxazole-trimethoprim 
(cotrimoxazole), vancomycin, and clindamycin in Mueller-
Hinton agar plates supplemented with 5% sheep blood accord-
ing to the standardized technique.17,18 Oxacillin-resistant strains 
(cleared area ≤ 19 mm) underwent subsequent determination 
of the minimum inhibitory concentration (MIC) of penicillin 
by using the broth microdilution method and were considered 
according to the criteria of the Clinical and Laboratory Stand-
ards Institute (CLSI), 200819 as follows: susceptible [S], MIC 
≤ 0.06 mg/mL; and resistant [R], MIC ≥ 0.12 mg/mL, for strains 
obtained from patients with meningitis. Oxacillin-resistant 
strains also underwent MIC determination for ceftriaxone and 
were considered as follows: susceptible, MIC ≤ 0.5 µg/mL; in-
termediately resistant (IR), MIC = 1 µg/mL; and fully resistant 
(FR), MIC ≥ 2 µg/mL for strains obtained from patients with 
meningitis.20 Oxacillin-susceptible strains (cleared area 
> 19 mm) were considered susceptible to penicillin and did 
not undergo MIC determination, according to the recommen-
dation of the CLSI, 2007.21 The cut-off points defi ned for peni-
cillin19 and ceftriaxone20 were applied to the results (MIC) ob-
tained during the study period, and maintained in a database. 
Serotyping was performed by use of the Neufeld Quel-
lung reaction, a technique previously described22 by using 
polyclonal antisera.11 
Data from April 1999 to April 2009 were obtained and the 
results were submitted to statistical analysis. The results were 
analyzed in two time periods, considering the reports on the 
increase in resistance rates over time.23,24 Only two periods of 
time were chosen because of the limited size of the sample.
For comparing the proportions of the pattern of antimicro-
bial susceptibility in the different time periods and age ranges, 
the chi-square test (χ2) was used. Tests of normality and homo-
geneity of the samples were used whenever necessary. The level 
for rejecting the null hypothesis was fi xed as 5% (P < 0.05).
The study was approved by the Committee on Ethics in 
Research of the Universidade Federal de Uberlândia (CEP/UFU, 
protocol 210/08).
RESULTS
From April 1999 to April 2009, 72 pneumococcal strains ob-
tained from patients with meningitis were sent to the IAL and 
assessed. Forty-six (63.9%) strains originated from males, 
and age ranged from one month to 82.2 years (mean, 18.4 
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± 22.9 years; median, 5.2 years; 25th percentile, 5.2 months; 
and 75th percentile, 36 years). The number of isolations per 
age bracket was 33 in children up to 24 months, two in chil-
dren from 25 to 60 months, nine in children from 61 months 
to 12 years, 23 in patients from over 12 to 60 years, and fi ve 
in patients older than 60 years. The number of samples stud-
ied per year obtained from 1999 to 2009 was 6, 11, 8, 7, 7, 8, 
5, 9, 6, 3, and 2, respectively. The sources of collection were 
cerebrospinal ﬂ uid in 66 samples (91.7%) and blood in six 
samples (8.3%). Overall lethality rate of 25% (18/72) was 
lower than that of children aged two years or less (36.4%) 
and that of adults over the age of 60 years (80%). 
Twenty-four different serotypes were identifi ed and the 
most common are shown in Table 1, according to the differ-
ent age brackets. 
Twenty (27.8%) oxacillin-resistant strains were de-
tected. According to the CLSI criteria, 2008,19 17 (23.6%) 
subsequently confi rmed penicillin resistance, which was 
limited to serotypes 14 (11 strains), 19F, 23F (two strains 
each), 6B, and 19A (one strain each). Resistance predomi-
nated in children aged up to two years (Table 2; P = 0.004) 
and in the 2005-2009 period as compared to the 1999-2004 
period (Table 2; P = 0.003). Ceftriaxone resistance was de-
tected in nine of the 17 penicillin-resistant strains, at a rate 
Table 1. Distribution of the pneumococcal serotypes according to the age bracket of patients hospitalized with 
meningitis from 1999 to 2009
Serotypes ≤ 60m % > 60m % Total %
14 16 45.8 3 8.1 19 26.3
19F 2 5.7 5 13.5 7 9.7
3 1 2.9 4 10.8 5 6.9
7F 2 5.7 3 8.1 5 6.9
6ª 3 8.5 1 2.7 4 5.6
6B 3 8.5 1 2.7 4 5.6
10ª 1 2.9 2 5.4 3 4.2
18C 3 8.5 0 0.0 3 4.2
23F 1 2.9 2 5.4 3 4.2
5 1 2.9 1 2.7 2 2.8
34 0 0 2 5.4 2 2.8
Others1 2 5.7 13 35.2 15 20.8
Total 35 100.0 37 100.0 72 100.0
1Others: ≤ 60 months - serotypes 1 and 18B (one of each); 
 > 60 months – serotypes 4, 7C, 9N, 10F, 11A, 18A, 
19A, 20, 23A, 28A, non-classifiable (one of each), serogroup H (two strains).
Table 2. Distribution of pneumococcal strains isolated from patients with meningitis, according to 
susceptibility to penicillin, age bracket, and isolation period
Age (months)            Susceptibility to penicillin   Total 
  Susceptible*   Resistant**  
Period (year) ≤ 24 > 24 ≤ 24 > 24  
 1999-2004 17 24 4 2 47 
 2005-2009 3 11 9 2 25 
Subtotal 20 35 13 4 72 
Total  55  17 72
*Presumed susceptibility by use of the oxacillin disk diffusion test. 
**According to the CLSI criterion, 2008.
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of 12.5% (9/72), 6.9% (5/72) being intermediate resist-
ance, and 5.6% (4/72) full resistance. Also for ceftriaxone, 
resistance predominated in children aged up to two years 
(Table 3; P = 0.039) and in the 2005-2009 period as com-
pared to the 1999-2004 period (Table 3; P = 0.000). The 
maximum penicillin and ceftriaxone MIC were 4 µg/mL 
and 2 µg/mL, respectively. No resistance to chlorampheni-
col, oﬂ oxacin, rifampicin or vancomycin was observed.
DISCUSSION
Despite the small size of the population studied, similari-
ties with the results of other national25-32 and Latin-Ameri-
can25-28 surveys could be identifi ed. The profi le of the most 
frequently found serotypes in developing countries has been 
confi rmed, 14, 19F, 3, 7F, 6A/6B, 10A, 18C, 23F, 5, and 1, with 
an emphasis on the high prevalence of serotypes 1 and 5, 
commonly found in Latin America.13,26,27,28
The SIREVA Project collected 2,584 invasive pneumococ-
cal strains from different Brazilian regions during a three-year 
period: 2006,26 2007,27 and 2008.28 The analysis of the most fre-
quently found serotypes in children with meningitis up to the 
age of fi ve years indicated a 76.9% coverage rate of the PCV7 
vaccine, including serotype 6A. According to data in Table 1, the 
vaccine coverage in the population under the age of fi ve years 
studied should be 71.3% (79.8% when including serotype 6A) 
and would not include serotypes 1, 3, and 5, also isolated. Nev-
ertheless, serotypes 6B, 14, 19F, and 23F, among which penicil-
lin-resistant strains can be found, would be covered (100% vac-
cine coverage). The PCV10 vaccine coverage in the population 
here studied would be 82.8% (91.3% with serotype 6A), and 
the PCV13 vaccine coverage would increase to 94.2%.
The comparison of the proportions according to age brack-
et (Table 1) suggests a predominance of serotypes 14, 6A, 6B, 
and 18C in children aged up to fi ve years and of serotype 3 in 
patients over that age, a fact also reported in other studies.31,32 
Serotype 3, associated with severe forms of pneumonia in 
adults,13,29 is also an important cause of invasive disease in new-
borns and infants, justifying its inclusion in a vaccine to protect 
children under the age of two years.13 In our survey, serotype 3 
is one of the most commonly found in patients with meningi-
tis, and also found in children under the age of two years. The 
high frequency of serotypes 14, 6A, and 6B in invasive disease, 
especially in infants with meningitis, has already been reported 
in national26-32 and Latin-American26-28 studies.
Although some serotypes have been associated with a 
particular disease, there is no exclusivity and different se-
rotypes can cause different diseases.13 Because they are 
non-completely dependent variables, the correlation of the 
serotype profi le with the disease type can be inﬂ uenced by 
other factors, such as temporality and age.13 However, sero-
type 18C has been more commonly associated with men-
ingitis13 and serotype 19A with pneumonia.29 In this study, 
serotype 18C was detected in children under the age of fi ve 
years (8.5%) and serotype 19A, in only one patient over that 
age. Despite its low frequency in Brazil25-29 and other Latin-
American countries, serotype 19A is associated with penicil-
lin resistance13,23,30-32 and is currently an important emerging 
serotype in the USA, after the release of the heptavalent con-
jugate vaccine for universal use.7,13
In this study, the penicillin-resistance rate was 23.6% 
(17/72 strains) when all age brackets were considered, and 
39.4% for ages up to two years (Table 2). Those fi gures are 
greater than the 15% found when considering the different 
ages and nosologies, and greater than the 29.6% found when 
considering children up to two years, in that same popula-
tion in 2003.33 Those fi gures are close to those found in pa-
tients hospitalized with meningitis at other places: 20.3% at 
different ages and 24.3% in children aged up to fi ve years at 
the Brazilian Federal District;32 36.4% in patients aged from 
one month to 15 years in the city of São Paulo;30 and, in the 
city of Salvador, overall rate of 15.2% and predominance in 
children under the age of fi ve years (35%) as compared with 
older children (9%).31
Table 3. Distribution of pneumococcal strains isolated from patients with meningitis according to susceptibility 
to ceftriaxone, age bracket, and isolation period
Age (months)              Susceptibility to ceftriaxone*   Total 
  Susceptible   Resistant  
Period (year) ≤ 24 > 24 ≤ 24 > 24  
 1999-2004 20 26 1 0 47 
 2005-2009 6 11 6 2 25 
Subtotal 26 37 7 2 72 
Total  63  9 72
*According to the NCCLS criterion, 2002.
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Signifi cant increases in the penicillin-resistance rates of 
invasive pneumococcal strains have been reported in Brazil, 
from 10.2% in 1993 to 27.9% in 2004.23 Those values can 
be compared with those of recently published Brazilian sur-
veys27,28 that apply the new categorization criteria for penicil-
lin.19 Analyzing the invasive pneumococcal strains obtained 
from patients with meningitis during the years 200727 and 
2008,28 the penicillin resistance rates for different ages was 
31.5% and for children up to two years of age 50.4%.27,28 
Penicillin resistance has been restricted to serotypes 14 (11 
strains), 19F, 23F (two strains each), 6B, and 19A (one of each), 
classically associated with drug resistance.13 Those are the so-
called “pediatric serotypes”, responsible for a large number of 
infectious episodes in children. The age-dependent intrinsic 
characteristics of immunogenicity and the extensive exposure 
to antimicrobial agents have contributed, respectively, to the 
predominance among younger children and the development 
of penicillin resistance.13,23 This study could confi rm the in-
crease in the proportion of penicillin-resistant strains related 
to age (39.4% up to two years versus 10.3% above that age; 
Table 2; P = 0.004) and to the time period (from 1999 to 2005, 
12.8%; and from 2005 to 2009, 44%; Table 2; P = 0.003). The 
tendency towards an increase in penicillin resistance in Brazil 
over time has already been demonstrated in a Brazilian study23 
and has been associated with the emergence and dissemina-
tion of two international pneumococcal clones denominated 
Spain9V-3 and Tennessee.14-18 Theses clones, which express the 
capsule of serotype 14 and are characterized by drug resist-
ance, have predominated in the southern and southeastern 
regions of Brazil since 1998. Of the 17 isolated penicillin-
resistant clones detected in the present study, 11 (64.7%) are 
serotype 14, and, thus, one can speculate that, at least partially, 
the increase in the proportion of resistant strains results from 
dissemination of the referred clones in that community. 
The nine ceftriaxone-resistant pneumococcal strains 
(fi ve IR strains and four FR strains) found in this study 
account for a 12.5% resistance rate, close to that reported 
in Brazilian laboratory surveillance studies26-28 when using 
the current cut-off points for ceftriaxone.20 Based on the 
invasive strains obtained from patients with meningitis in 
2006,26 2007,27 and 2008,28 a 11.9% rate of ceftriaxone resist-
ance was detected, 9.1% being IR and 2.8% FR. Considering 
only children aged up to fi ve years, admitted with invasive 
disease (23.2% with meningitis) from 1999 to 2009, a 5.6% 
ceftriaxone-resistance rate was found in the same popula-
tion assessed in this study.34 
The documented resistance rates for both penicillin and 
ceftriaxone vary depending on factors, such as geographical 
location, sample size, time and duration of the assessment, pa-
tient’s age, and nosology. Usually, resistance tends to predomi-
nate in children,23,31-33 especially in those with meningitis,23,34 
with increasing frequency23,32,34 and intensity23 over time in the 
communities not undergoing universal vaccination. 
The most appropriate methodology to estimate pneu-
mococcal disease rates in a community consists in clinical 
population surveillance, based on the laboratory identi-
fication of the agent.7 That requires up-to-date data of 
population census and consistent techniques of accurate 
pneumococcal isolation and identification. This study 
used laboratory surveillance of invasive hospital-based 
strains, which is a limitation to conclusions. Epidemio-
logical data should be carefully extrapolated, particu-
larly for those diseases diagnosed and treated outside the 
hospital setting. 
Local or regional pattern of drug susceptibility should 
be monitored to support the choice of the best empiric 
therapeutic regimen for invasive pneumococcal diseases. 
For the specifi c directed treatment, the antibiotic choice is 
inﬂ uenced by the laboratory categorization (susceptible or 
resistant, according to the MIC) and every effort should be 
made in the search for the causative agent and determina-
tion of its susceptibility to antimicrobial agents. 
Finally, the greatest impact on morbidity and mortal-
ity of pneumococcal meningitis results from its prevention 
through the universal use of the conjugate vaccine in the 
target population, similarly to what happened with the Hib 
and pneumococcal infection in the USA.7 The decision of 
the Brazilian Ministry of Health to include the pneumococ-
cal conjugate vaccine in the National Immunization Calen-
dar of all children aged up to two years from this year on is 
of paramount importance.
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